Dengue has emerged as the most common mosquito-borne viral disease of humans in the past three decades. There are no available vaccines or antivirals against DENV. Currently, vector control is the only method for prevention of the disease. Development of a successful vaccine would require for it to be effective against all four DENV serotypes, economical, and provide long-term protection. Antivirals directed against one or more stages of the virus life cycle are likely to form an important part of dengue disease therapeutics. The strategies that have been used in the past towards development of an effective antiviral against dengue, as well as those being employed currently are discussed in light of information from structural biology, computational biology and molecular virology, highlighting the potential opportunities and obstacles to their use.

from Mayuri, Elisa La Bauve and Richard J. Kuhn in Frontiers in Dengue Virus Research

Further reading: Dengue Virus

Labels: dengue, dengue fever, Dengue therapy, Dengue vaccine, dengue virus